查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1422943

2024-2032 年按 MRSA 類型（醫院獲得性、社區獲得性）、藥物類別、疾病適應症、給藥途徑、配銷通路和地區分類的 MRSA 藥物市場

MRSA Drugs Market by MRSA Type (Hospital-Acquired, Community-Acquired ), Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

2023年，全球MRSA藥物市場規模達到38億美元。展望未來， IMARC Group預計到2032年市場規模將達到50億美元，2024-2032年複合年成長率（CAGR）為3.11%。抗生素抗藥性菌株的盛行率不斷上升，由於住院時間延長而在醫療機構中持續接觸多重抗藥性微生物，以及臨床試驗數量不斷增加，是推動市場發展的一些關鍵因素。

抗甲氧西林金黃色葡萄球菌 (MRSA) 是由抗抗生素金黃色葡萄球菌菌株引起的感染，通常發生在接受外科手術、接受靜脈插管或皮膚接觸的患者身上。 MRSA藥物用作抗甲氧西林金黃色葡萄球菌感染的抗菌劑，以殺死或抑制它。它們抑制病原體的作用，同時增強患者的細胞合成和免疫力。最常見的 MRSA 藥物包括甲氧芐啶-磺胺甲噁唑、克林黴素、米諾環素、利奈唑胺或多西環素。這些藥物一般作為口服藥物使用，療程通常為七至十天。 MRSA 感染可能來自醫院或社區，因此 MRSA 的治療有時可能需要口服藥物和靜脈注射 (IV) 藥物，具體取決於嚴重程度。有多種 MRSA 藥物可用於治療不同類型的感染，包括皮膚感染、骨骼感染、菌血症，甚至動物的人畜共通傳染病。

MRSA 藥品市場趨勢：

大眾中抗生素抗藥性菌株的盛行率不斷上升是推動市場成長的重要因素。這可以歸因於全球範圍內院內感染（HAI）病例數量的增加。此外，由於住院時間延長，醫療機構中持續接觸多重抗藥性微生物，導致繼發性院內感染的發生，進而推動了市場的發展。除此之外，越來越多的老年人口更容易感染抗甲氧西林金黃色葡萄球菌（MRSA），這也為市場提供了動力。此外，人們對不同形式的細菌感染的認知不斷增強，導致耐甲氧西林金黃色葡萄球菌 (MRSA) 藥物的使用量增加。與此一致的是，大量的產品創新、越來越多的臨床試驗以及新藥物變體的引入正在市場上創造利潤豐厚的成長機會。然而，開發新型 MRSA 藥物變體所需的高成本是市場成長的主要限制因素。相反，各種診斷工具的技術不斷發展，以及篩選抗生素抗藥性菌株的臨床試驗計畫數量不斷增加，正在創造積極的市場前景。主要參與者進行的廣泛研發（R＆D）活動進一步推動了市場。促進市場發展的其他一些因素包括針對現有產品的學名藥的出現、透過線上和線下有組織的平台輕鬆獲得抗生素、快速城市化以及醫療支出的增加。

本報告回答的關鍵問題：

  • 迄今為止，全球 MRSA 藥物市場表現如何？未來幾年將如何表現？
  • 全球 MRSA 藥物市場的促進因素、限制因素和機會是什麼？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的 MRSA 藥物市場？
  • 基於 MRSA 類型的市場分類是怎樣的？
  • 根據藥物類別分類的市場是怎麼樣的？
  • 根據疾病跡象，市場的細分是什麼？
  • 根據給藥途徑，市場的分化為何？
  • 基於配銷通路的市場區隔是什麼？
  • 全球MRSA藥物市場的競爭結構如何？
  • 全球 MRSA 藥物市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球 MRSA 藥品市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依 MRSA 類型

  • 醫院獲得性 (HA-MRSA)
    • 市場走向
    • 市場預測
  • 社區型 (CA-MRSA)
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依藥物類別

  • 脂肽
    • 市場走向
    • 市場預測
  • 噁唑烷酮類
    • 市場走向
    • 市場預測
  • 頭孢菌素
    • 市場走向
    • 市場預測
  • 四環素
    • 市場走向
    • 市場預測
  • 葉酸拮抗劑
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依疾病適應症

  • 皮膚感染
    • 市場走向
    • 市場預測
  • 骨骼和關節感染
    • 市場走向
    • 市場預測
  • 菌血症
    • 市場走向
    • 市場預測
  • 動物感染
    • 市場走向
    • 市場預測

第 9 章：市場區隔：依管理途徑

  • 口服給藥
    • 市場走向
    • 市場預測
  • 腸外給藥
    • 市場走向
    • 市場預測

第 10 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 零售藥局
    • 市場走向
    • 市場預測
  • 網路藥局
    • 市場走向
    • 市場預測

第 11 章：市場區隔：按地區

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 12 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 13 章：價值鏈分析

第 14 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 15 章：價格分析

第16章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • Basilea Pharmaceutica Ltd
    • Crystal Genomics Inc.
    • Cumberland Pharmaceuticals Inc
    • Melinta Therapeutics Inc
    • Paratek Pharmaceuticals, Inc.
    • Pfizer Inc
Product Code: SR112024A6905

Abstract

The global MRSA drugs market size reached US$ 3.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.0 Billion by 2032, exhibiting a growth rate (CAGR) of 3.11% during 2024-2032. The rising prevalence of antibiotic resistant strains development, continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission and the growing number of clinical trials represent some of the key factors driving the market.

Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of staphylococcus aureus that generally occurs in patients who undergo surgical procedures, receive intravenous tubing, or come in contact with each other skin-to-skin. The MRSA drugs are used as antimicrobial agents against methicillin-resistant staphylococcus aureus infection in order to kill or restrain it. They inhibit the actions of pathogens while enhancing the patient's cellular synthesis and immunity. The most common MRSA drugs consist of trimethoprim-sulfamethoxazole, clindamycin, minocycline, linezolid, or doxycycline. These drugs are generally used as oral medication, usually on a course of seven to ten days. MRSA infections can arise from hospitals or from community, hence the treatment for MRSA can sometimes involve the administration of oral medications and intravenous (IV) medications, depending on the severity. There are a wide variety of MRSA drugs available that can be used for the treatment of different types of infections, including skin infections, bone infections, bacteremia, and even zoonotic infections in animals.

MRSA Drugs Market Trends:

The rising prevalence of antibiotic resistant strains development among the masses is a significant factor driving the growth of the market. This can be attributed to the increase in the number of cases of hospital-acquired infections (HAIs) on the global level. Also, the continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission is resulting in the development of secondary nosocomial infections, thereby propelling the market. In addition to this, the growing geriatric population that is more susceptible to developing MRSA infections is providing an impetus to the market. Moreover, the augmenting awareness regarding different forms of bacterial infection is leading to a higher uptake of MRSA drugs. In line with this, numerous product innovations, growing number of clinical trials and the introduction of novel drug variants are creating lucrative growth opportunities in the market. However, the high costs involved in developing novel MRSA drug variants is acting as major growth restraining-factor for the market. On the contrary, continual technological developments in various diagnostic tools, along with the increasing number of clinical trial programs for the screening of antibiotic resistant strains of bacteria, are creating a positive market outlook. The market is further impelled by extensive research and development (R&D) activities conducted by the key players. Some of the other factors contributing to the market include the emergence of generic drugs against presently available products, easy availability of antibiotics across online and offline organized platforms, rapid urbanization, and increasing medical expenditure.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global MRSA drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on MRSA type, drug class, disease indication, route of administration, and distribution channel.

MRSA Type Insights

Hospital-Acquired (HA-MRSA)

Community-Acquired (CA-MRSA)

The report has provided a detailed breakup and analysis of the MRSA drugs market based on the MRSA type. This includes Hospital-Acquired (HA-MRSA) and Community-Acquired (CA-MRSA). According to the report, Hospital-Acquired (HA-MRSA) represented the largest segment.

Drug Class Insights

Lipopeptides

Oxazolidinones

Cephalosporin

Tetracycline

Folate Antagonist

Others

The report has provided a detailed breakup and analysis of the MRSA drugs market based on the drug class. This includes lipopeptides, oxazolidinones, cephalosporin, tetracycline, folate antagonist, and others. According to the report, lipopeptides represented the largest segment.

Disease Indication Insights

Skin Infections

Bone and Joint Infections

Bacteremia

Animal Infections

The report has provided a detailed breakup and analysis of the MRSA drugs market based on the disease indication. This includes skin infections, bone and joint infections, bacteremia, and animal infections. According to the report, skin Infections represented the largest segment.

Route of Administration Insights

Oral Administration

Parenteral Administration

The report has provided a detailed breakup and analysis of the MRSA drugs market based on the route of administration. This includes oral administration and parenteral administration. According to the report, parenteral administration represented the largest segment.

Distribution Channel Insights

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

A detailed breakup and analysis of the MRSA drugs market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for MRSA drugs. Some of the factors driving the North America MRSA drugs market include the rising medical expenditure, the increasing number of clinical trial programs, extensive research and development (R&D) activities conducted by key players, etc.

Competitive Landscape

The report has also provided a comprehensive analysis of the competitive landscape in the global MRSA drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AbbVie Inc., Basilea Pharmaceutica Ltd, Crystal Genomics Inc., Cumberland Pharmaceuticals Inc., Melinta Therapeutics Inc, Paratek Pharmaceuticals, Inc., Pfizer Inc, etc.

Key Questions Answered in This Report:

  • How has the global MRSA drugs market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global MRSA drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive MRSA drugs markets?
  • What is the breakup of the market based on the MRSA type?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the disease indication?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What is the competitive structure of the global MRSA drugs market?
  • Who are the key players/companies in the global MRSA drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global MRSA Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by MRSA Type

  • 6.1 Hospital-Acquired (HA-MRSA)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Community-Acquired (CA-MRSA)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Lipopeptides
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Oxazolidinones
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cephalosporin
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Tetracycline
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Folate Antagonist
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Disease Indication

  • 8.1 Skin Infections
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Bone and Joint Infections
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Bacteremia
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Animal Infections
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Oral Administration
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Parenteral Administration
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 Drivers, Restraints, and Opportunities

  • 12.1 Overview
  • 12.2 Drivers
  • 12.3 Restraints
  • 12.4 Opportunities

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AbbVie Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Basilea Pharmaceutica Ltd
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
    • 16.3.3 Crystal Genomics Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
    • 16.3.4 Cumberland Pharmaceuticals Inc
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
    • 16.3.5 Melinta Therapeutics Inc
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
    • 16.3.6 Paratek Pharmaceuticals, Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Pfizer Inc
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis

List of Figures

  • Figure 1: Global: MRSA Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: MRSA Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: MRSA Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: MRSA Drugs Market: Breakup by MRSA Type (in %), 2023
  • Figure 5: Global: MRSA Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 6: Global: MRSA Drugs Market: Breakup by Disease Indication (in %), 2023
  • Figure 7: Global: MRSA Drugs Market: Breakup by Route of Administration (in %), 2023
  • Figure 8: Global: MRSA Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 9: Global: MRSA Drugs Market: Breakup by Region (in %), 2023
  • Figure 10: Global: MRSA Drugs (Hospital-Acquired (HA-MRSA)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: MRSA Drugs (Hospital-Acquired (HA-MRSA)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: MRSA Drugs (Community-Acquired (CA-MRSA)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: MRSA Drugs (Community-Acquired (CA-MRSA)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: MRSA Drugs (Lipopeptides) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: MRSA Drugs (Lipopeptides) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: MRSA Drugs (Oxazolidinones) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: MRSA Drugs (Oxazolidinones) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: MRSA Drugs (Cephalosporin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: MRSA Drugs (Cephalosporin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: MRSA Drugs (Tetracycline) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: MRSA Drugs (Tetracycline) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: MRSA Drugs (Folate Antagonist) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: MRSA Drugs (Folate Antagonist) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: MRSA Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: MRSA Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: MRSA Drugs (Skin Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: MRSA Drugs (Skin Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: MRSA Drugs (Bone and Joint Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: MRSA Drugs (Bone and Joint Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: MRSA Drugs (Bacteremia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: MRSA Drugs (Bacteremia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: MRSA Drugs (Animal Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: MRSA Drugs (Animal Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: MRSA Drugs (Oral Administration) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: MRSA Drugs (Oral Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: MRSA Drugs (Parenteral Administration) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: MRSA Drugs (Parenteral Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: MRSA Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: MRSA Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: MRSA Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Global: MRSA Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Global: MRSA Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Global: MRSA Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: North America: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: North America: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: United States: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: United States: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Canada: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Canada: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Asia-Pacific: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Asia-Pacific: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: China: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: China: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Japan: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Japan: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: India: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: India: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: South Korea: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: South Korea: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Australia: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Australia: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Indonesia: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Indonesia: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Europe: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Europe: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Germany: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Germany: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: France: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: France: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: United Kingdom: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: United Kingdom: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Italy: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Italy: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Spain: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Spain: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Russia: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Russia: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Others: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Others: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Latin America: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Latin America: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Brazil: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Brazil: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Mexico: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Mexico: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Others: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: Others: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Middle East and Africa: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 91: Middle East and Africa: MRSA Drugs Market: Breakup by Country (in %), 2023
  • Figure 92: Middle East and Africa: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 93: Global: MRSA Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 94: Global: MRSA Drugs Industry: Value Chain Analysis
  • Figure 95: Global: MRSA Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: MRSA Drugs Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: MRSA Drugs Market Forecast: Breakup by MRSA Type (in Million US$), 2024-2032
  • Table 3: Global: MRSA Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 4: Global: MRSA Drugs Market Forecast: Breakup by Disease Indication (in Million US$), 2024-2032
  • Table 5: Global: MRSA Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 6: Global: MRSA Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 7: Global: MRSA Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: MRSA Drugs Market: Competitive Structure
  • Table 9: Global: MRSA Drugs Market: Key Players